Related Experiment Video
Updated: Jan 30, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Mathias Vormehr1,2, Özlem Türeci1, Ugur Sahin1,2,3
1Biopharmaceutical New Technologies (BioNTech) Corporation, 55131 Mainz, Germany; email: mathias.vormehr@biontech.de , oezlem.tuereci@biontech.de.
Abstract:
T cells are key effectors of anticancer immunity. They are capable of distinguishing tumor cells from normal ones by recognizing major histocompatibility complex-bound cancer-specific peptides. Accumulating evidence suggests that peptides associated with T cell-mediated tumor rejection arise predominantly from somatically mutated proteins and are unique to every patient's tumor. Knowledge of an individual's cancer mutanome (the entirety of cancer mutations) allows harnessing this enormous tumor cell-specific repertoire of highly immunogenic antigens for individualized cancer vaccines. This review outlines the preclinical and clinical state of individualized cancer vaccine development and the challenges ahead.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations

